THERAPY DOSSIER · th-32e47d062262

Nobiletin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32538091 ↗2020Reported benefit

Nobiletin Protects against Acute Liver Injury via Targeting c-Jun N-Terminal Kinase (JNK)-Induced Apoptosis of Hepatocytes.

MouseChemical/toxinC57BL/6Male10 mg/kgPretreatment before concanavalin A

Model: Concanavalin A-induced acute liver injury

Nobiletin pretreatment lowered ALT and AST, reduced reactive oxygen species and TNF-alpha and interferon-gamma release, promoted hepatocyte proliferation, reduced apoptosis and suppressed JNK signalling.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…